Exact Sciences gains 6% following data on blood-based colorectal cancer test [Seeking Alpha]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Seeking Alpha
Data showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy. Sensitivity is a measure of true positivity for a test, while specificity measures true negativity. The study used 3,000 blood samples, as well as more than 90 advanced precancerous lesions, and 60 case-collected colorectal cancer samples. Exact Sciences ( EXAS ) currently markets the Cologuard test for colorectal cancer, which is stool-based. Recommended For You More Trending News About EXAS Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- ESMO 2024: Exact Sciences unveils results from cancer algorithm trial [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024 [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024Business Wire
- Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $75.00 price target on the stock.MarketBeat
- Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Piper Sandler from $75.00 to $85.00. They now have an "overweight" rating on the stock.MarketBeat
EXAS
Earnings
- 7/31/24 - Beat
EXAS
Sec Filings
- 9/19/24 - Form 4
- 9/18/24 - Form 144
- 8/6/24 - Form 4
- EXAS's page on the SEC website